The positive preliminary findings from Disc Medicine's Phase 2 BEACON trial indicate that bitopertin has the potential to be an effective treatment for EPP and XLP. This news has a direct impact on the company's stock price, as it demonstrates the potential success of their product in the market. The significant increase in sunlight tolerance and improvements in patient quality of life measures are important factors that contribute to the positive outlook for the company and its stock price.